The Survey of Effective Agents on Factor VIII and IX Inhibitors in Patients with Hemophilia A and B in Kermanshah Province
Journal Title: Iranian Journal of Blood and Cancer - Year 2015, Vol 7, Issue 4
Abstract
Background: Hemophilia is the most frequent severe hereditary hemorrhagic disease due to deficiency of coagulation factors VIII (Hemophilia A) or IX (Hemophilia B) in plasma. We aimed to identify patients with hemophilia in Kermanshah, Iran and assess the incidence of inhibitors in this population and its associated factors. Methods: This study was conducted on patients with hemophilia A and B admitted in hospitals of Kermanshah city, referred to coagulation laboratory of Kermanshah blood transfusion organization. Variables including age, sex, family history of the patients in terms of history of hemophilia and inhibitor formation, development of inhibitor in patients, age at starting the treatment, blood group, severity of hemophilia, average of factors received per month and liver disease were assessed in patients. Results: Of 123 patients with hemophilia A, 119 (96.7%) were men. The mean±SD age of patients with hemophilia A was 25.9±15.74 years. Only five men had developed factor VIII inhibitor. Of 25 patients with hemophilia B, 24 (96%) were men with a mean±SD age of 21.7±15.71 years. Factor IX inhibitor was not detected in any patient. There was no association between incidence of inhibitors and age at the onset of the treatment, family history of hemophilia, blood group, severity of hemophilia, average of received factor per month and liver disease. However, a positive association between incidence of inhibitors and family history of inhibitors was found (P<0.05). Conclusion: Association between family history of inhibitor and incidence of inhibitor formation in hemophilic patients was a new finding. Therefore this outcome and genetic evaluation of these for finding relevant mutations should be considered.
Authors and Affiliations
Mehrdad Payandeh, N Amirifard, Edris Sadeghi, Masoud Sadeghi, M Choubsaz, F Noor Mohammadi Far
Keywords
Related Articles
- EP ID EP281564
- DOI -
- Views 95
- Downloads 0
WHO Recommendations for the production, control and regulation of human plasma for fractionation
This article has no abstract.
Conversion from Platelet-Rich Plasma Platelet Production to Buffy Coat Platelet Component Production: Benefits and Limitations
Blood transfusion centers are under considerable pressure to produce platelet concentrates with high quality and safety due to the short shelf life of 3-5 days as well as possible bacterial and viral contaminations. For...
Correlation Between Demographic and Laboratory Variables in Adult Patients with Acute Idiopathic Thrombocytopenic Purpura in West Iran
Background: Idiopathic thrombocytopenic purpura is an autoimmune blood disorder in which platelet destruction is mediated by anti-platelet antibodies. There are two forms of ITP: acute and chronic. The aim of the present...
Allele Frequencies of HLA-A, B and DRB1 among People of Fars Ethnicity Living in Tehran
Background: Human leukocyte antigens (HLA) are polymorphic cell surface proteins. Distribution of HLA alleles vary among different racial and ethnic populations in unrelated stem cell registries. Determination of HLA all...
Relation between the Short Term Health Related Quality of Life and Various Types of Medical Treatment in Patients with Idiopathic Chronic Thrombocytopenia
Background:Chronic Idiopathic Thrombocytopenic Purpura (ITP) is an autoimmune disorder characterized by a low platelet count due to reduced production and higher destruction of the platelets. Therapy is aimed at increasi...